Effect of clovoxamine fumarate on the electrocardiogram

The electrocardiographic effects of clovoxamine, an antidepressant that inhibits the neuronal uptake of both noradrenaline and 5-hydroxytryptamine, have been studied. High speed electrocardiograms were recorded on 28 patients with depressive illness before and after 4 weeks treatment with either clovoxamine or placebo. No patient had clinical evidence of cardiovascular disease. The ECG measurements were carried out blind to patient, treatment and treatment interval. No statistically significant changes in the sinus cycle length, PR, QRS and QTc intervals, or T-wave height were found after treatment with active drug or placebo, showing that clovoxamine has no clinically important effects on the ECG when given in therapeutic doses to patients free from serious physical disease.